Creative BioMart Biomarker has established a mature biomarker detection platform, which can provide customers with fast, accurate and sensitive vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR) detection services.
Our testing services are only suitable for scientific research, not intended for clinical diagnosis and testing.
|
VEGF Testing |
| Analyte: |
VEGF |
| Synonyms: |
vascular endothelial growth factor, vascular permeability factor, VPF |
| Sample Type: |
plasma, serum, cell culture supernatants or other biological fluids |
| Assay Platform: |
ELISA, ECL |
| Biomarker Application Area: |
breast cancer, liver cancer, non-small cell lung cancer, colorectal cancer, etc. |
| * Perform three replicate tests on each sample, and include appropriate controls in each assay. |
| * VEGF detection service is applicable to the test of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3, etc. Please contact us for specific test information. |
Assay Background
Figure 1. Actions of different VEGF isoforms on the 3 major types of VEGFRs (Alsohaimi, 2019)
VEGF, also known as vascular permeability factor (VPF), is an important growth factor and signaling molecule that can drive tumor angiogenesis. The VEGF family includes VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and placental growth factor (PlGF). VEGF-A promotes neovascularization and is related to vascular permeability. VEGF-C and VEGF-D are involved in the formation of new blood vessels and new lymphatic vessels in cancer tissues. VEGF functions by binding to VEGFR expressed on the surface of human vascular endothelial cells. VEGFR is a type of tyrosine kinase receptor, which is divided into three types: VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-1 and VEGFR-2 are mainly distributed on the surface of tumor vascular endothelium and regulate tumor angiogenesis. VEGFR-3 is mainly distributed on the surface of lymphatic endothelium, which is related to the formation of tumor lymphatics. Angiogenesis is important in tumorigenesis and is closely related to tumor growth and metastasis.
Workflow of Biomarker Detection Services at Creative BioMart Biomarker
Customers provide: samples, reagents/kits (reagents/kits can also be provided or purchased by our company).
We provide: remaining samples and reagents, complete experimental reports (including experimental raw data, experimental procedures, instrument and reagent information, and professional result analysis).
Test cycle: 10 working days or less.
Why Choose Creative BioMart Biomarker for VEGF Detection Service?
- Multiple molecular tests & technology platforms
We provide testing services for VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGFR-1, VEGFR-2, VEGFR-3, etc. The services involve two technical platforms, ELISA and ECL, and can fully meet the experimental needs of different researchers.
- Experienced experts team
We have many experts with rich experience in biomarker testing. They always treat each test with a rigorous attitude and can always provide customers with accurate, precise and repeatable test results.
- Suitable for multiple sample types
Our biomarker testing service is applicable to several sample types, including serum, plasma, cell culture supernatant, etc. If your sample type is not common, you can contact us at any time to inquire about the testing service for your sample type.
- Fast testing and reasonable price
We have been committed to providing customers with efficient services to ensure that the experimental results are delivered within the predetermined time. Our testing services have reasonable and competitive prices in the industry, which can help customers reduce research costs.
If you are interested in our services, please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Murukesh, N.; et al. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer. 2010, 102(1): 8–18.
- Macedo, F.; et al. Gastric cancer and angiogenesis: is VEGF a useful biomarker to assess progression and remission? Journal of Gastric Cancer. 2017, 17(1): 1-10.
- Alsohaimi, A. The pathogenic role of vascular endothelial growth factor (VEGF) in skin diseases. Advances in Medicine and Medical Research. 2019, 2(1): 27-37.
